Capital Fund Management (CFM)
MLTX icon

Capital Fund Management (CFM)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
65,394
+54,134
+481% +$981K 0.01% 1614
2026
Q1 		$210K Buy
+11,260
New +$187K ﹤0.01% 2000
2024
Q3 		– Sell
-29,243
Closed -$1.29M – 2086
2024
Q2 		$1.29M Buy
+29,243
New +$1.24M ﹤0.01% 1536

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Fund Management (CFM)'s MLTX Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its MoonLake Immunotherapeutics (MLTX) stake by 481% in Q2 2026, buying an estimated $981K and bringing the position to 65,394 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #1614.

Capital Fund Management (CFM) first reported a position in MLTX in Q2 2024 and has held it in 3 quarters since. The position peaked at $1.29M in Q2 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Capital Fund Management (CFM) held 65,394 shares of MoonLake Immunotherapeutics worth $1.27M as of Q2 2026.
  • Capital Fund Management (CFM) bought 54,134 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $981K.
  • MoonLake Immunotherapeutics made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1614 holding.
  • Capital Fund Management (CFM) first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 3 quarters since.
  • Capital Fund Management (CFM)'s MoonLake Immunotherapeutics position peaked at $1.29M in Q2 2024.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.